Abstract
Introduction A cohort of COVID-19 convalescent volunteers allowed the study of neutralizing (nAb) and ligand antibodies kinetics by providing sequential samples during a median of 100 days after onset of disease.
Material and Methods A cohort of previously RT-PCR+ve (detected by nasopharyngeal swab during the acute phase), male convalescent patients, all with mild symptoms, were enrolled on serial blood sample collection for evaluation of longitudinal nAb titers and anti-nucleocapsid (NP) antibodies (IgM, IgG and IgA). Nabs were detected by a cytopathic effect-based virus neutralization test (CPE-based VNT), carried out with SARS-CoV-2 (GenBank: MT350282)
Results A total of 78 male volunteers provided 316 samples, spanning a total of 4820 days of study. Although only 25% of donors kept nAb titers ≥160, after a median of 100 days after the onset of disease, there was a high probability of sustaining nAB titers ≥160 in volunteers whose initial nAb titer was ≥1280, weight ≥ 90kg or BMI classified as overweight or obese, evidenced by Kaplan-Meier estimates and Cox hazard regression. There was no correlation between ABO group, ABO antibody titers and persistent high nAb titers. High IgG anti-NP (S/CO ≥5.0) is a good surrogate for detecting nAB ≥160, defined by ROC curve (sensitivity = 90.5%; CI95% 84.5-94.7%)
Conclusion Selection of CCP donors for multiple collections based on initial high nAb titers (≥1280) or overweight/obese (BMI) provides a simple strategy to achieve higher quality in CCP programs. High IgG anti-NP levels can also be used as surrogate markers for high nAb screening.
Competing Interest Statement
CPS is funded by Grant - 2018/23680-0 (FAPESP); DBA by Grant 88887.131387/2016- 00 (CAPES), RRGM by Grant 2017/24769-2 (FAPESP) and ELD by Grants 2016/20045-7 and 2020/06409-1 (FAPESP). This project was partially supported by the initiative Todos Pela Saude.
Funding Statement
This project was partially supported by the initiative Todos Pela Saude
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study was approved by our IRB and the Brazilian Commission on Ethics and Research (CONEP) under request CAAE: 30259220.4.2001.5461.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
* Conflict of interests: CPS is funded by Grant - 2018/23680-0 (FAPESP); DBA by Grant 88887.131387/2016- 00 (CAPES), RRGM by Grant 2017/24769-2 (FAPESP) and ELD by Grants 2016/20045-7 and 2020/06409-1 (FAPESP). This project was partially supported by the initiative Todos Pela Saude.
Data Availability
I hereby state that all data will be availabe under special request
